COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans

• Published in: JAMA network open Vol. 7; no. 7; p. e2419258
• Main Authors: Laniece Delaunay, Charlotte, Mazagatos, Clara, Martínez-Baz, Iván, Túri, Gergo, Goerlitz, Luise, Domegan, Lisa, Meijer, Adam, Rodrigues, Ana Paula, Sève, Noémie, Ilic, Maja, Latorre-Margalef, Neus, Lazar, Mihaela, Maurel, Marine, Melo, Aryse, Andreu Ivorra, Blanca, Casado, Itziar, Horváth, Judit Krisztina, Buda, Silke, Bennett, Charlene, de Lange, Marit, Guiomar, Raquel, Enouf, Vincent, Mlinaric, Ivan, Samuelsson Hagey, Tove, Dinu, Sorin, Rumayor, Mercedes, Castilla, Jesús, Oroszi, Beatrix, Dürrwald, Ralf, O'Donnell, Joan, Hooiveld, Mariëtte, Gomez, Verónica, Falchi, Alessandra, Kurecic Filipovic, Sanja, Dillner, Lena, Popescu, Rodica, Bacci, Sabrina, Kaczmarek, Marlena, Kissling, Esther
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 01.07.2024
• Subjects: Aged; Aged, 80 and over; Case-Control Studies; COVID-19 - epidemiology; COVID-19 - prevention & control; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - therapeutic use; Europe - epidemiology; European People; Female; Humans; Infectious Diseases; Life Sciences; Male; Middle Aged; Online Only; Original Investigation; SARS-CoV-2 - immunology; Seasons; Vaccination - statistics & numerical data; Vaccine Efficacy; Europe

In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns. To estimate the effectiveness of COVID-19 vaccines administered in autumn and winter 2022 to 2023 against symptomatic SAR...